Braeburn Pharmaceuticals and Camurus announced the positive top-line results from the pivotal phase 3 randomized, double-blind, double-dummy, active controlled trial of weekly and monthly injections of buprenorphine. Apart
PKC412 is indicated to treat AML in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The
Parsabiv is a calcimimetic agent where a healthcare provider can administer it intravenously three times per week at the end of a hemodialysis session. A calcimimetic is a
The Prospective Randomized Evaluation of CelecoxibIntegrated Safety vs. Ibuprofen Or Naproxen (Precision) demonstrated that Celebrex has similar cardiovascular risk as compared to prescription doses Of Ibuprofen and Naproxen. The findings contradict some of the researchers’ belief
The approval allows the company to use Ibrance in combination with an aromatase inhibitor. It also allows the use of Ibrance in combination with fulvestrant to treat women who
Drug resistance contributes to nearly 600,000 cancer deaths in the US per year. The partners will use Watson's computational and machine learning methods to study drug resistance in
The partial hold was placed on the study in August of this year, requesting chemistry, manufacturing, and controls data and clarifications to several trial design questions. Now that
The companies formed a clinical trial collaboration to evaluate the combination treatment. The dose-escalation part assessing IPI-549 as a monotherapy in Infinity’s phase 1 trial is continuing, and
RAS mutations appear in about 30% of all cancers. They are also present in nearly 90% of pancreatic cancers and occur frequently in colon cancer, lung cancer and melanoma.
Mylan has submitted a biologics license application (BLA) for MYL-1401O via the 351(K) pathway. The proposed biosimilar version of trastuzumab is indicated to treat several breast and gastric
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.